Treximet ™ Pharmacy Budget Impact Model Database Validation Study
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this retrospective claims database study was to compare the change in
migraine-related prescription (i.e. NSAIDs, Opioids, Ergots) utilization among migraine
suffers following initiation of Treximet ™ (sumatriptan/naproxen) compared with subjects
initiating treatment with other orally available triptans. The study was used to validate the
migraine-related prescription utilization patterns predicted by the Treximet ™ Budget Impact
Model.
The SourceLx dataset from the family of Wolters Kluwer databases was used for this analysis.
The database contains 30% of prescription claims filled in the United States (US),
approximately 160 million patient lives. The data has broad representative coverage at both
the geographic and payment levels.